Author
Christine Mian
Other affiliations: University of Texas Southwestern Medical Center
Bio: Christine Mian is an academic researcher from University of Vienna. The author has contributed to research in topics: Bladder cancer & Cytology. The author has an hindex of 28, co-authored 74 publications receiving 2649 citations. Previous affiliations of Christine Mian include University of Texas Southwestern Medical Center.
Papers published on a yearly basis
Papers
More filters
TL;DR: These data show that age-associated urodynamic changes in both sexes are comparable for a number of parameters and provide an explanation for the fact that aging women report comparable voiding symptoms as men and suggest a primary, non-sex-specific aging process of the urinary bladder.
196 citations
TL;DR: P16INK4a is a tumor suppressor gene that plays a central role in the regulation of the cell cycle in squamous cervical cancers, and overexpression of it is induced by HPV and associated with the carcinogenesis of cervical epithelia.
Abstract: p16INK4a is a tumor suppressor gene that plays a central role in the regulation of the cell cycle In squamous cervical cancers, overexpression of p16INK4a is induced by HPV and associated with the carcinogenesis of cervical epithelia The aim of this study was to determine whether immunostaining of
186 citations
TL;DR: Investigating the diagnostic value of the newly developed immunocytochemical test, Immunocyt, which detects cellular markers specific for transitional cell cancer in the voided urine of patients with bladder cancer found it to be a noninvasive, highly sensitive test for detecting transitional cell carcinoma of all grades and stages.
180 citations
TL;DR: Nomograms that incorporate urinary NMP22, cytology, age and gender to predict with high accuracy the probability of disease recurrence and progression in patients with Ta, T1, and/or CIS bladder TCC are developed and validated.
160 citations
TL;DR: CIN1 cases with diffuse p16ink4a staining had a significantly higher tendency to progress to a high-grade lesion than p16INK4a-negative cases, which may have the potential to support the interpretation of low-grade dysplastic lesions of the cervix uteri.
Abstract: The aim of the study was to evaluate the immunohistochemical expression of p16INK4a as a marker of progression risk in low-grade dysplastic lesions of the cervix uteri. p16INK4a immunohistochemistry was performed on 32 CIN1 with proven spontaneous regression of the lesion in the follow-up (group A), 31 (group B) with progression to CIN3 and 33 (group C) that were randomly chosen irrespective of the natural history of the lesion. p16INK4a staining pattern was scored as negative (less than 5% cells in the lower third of dysplastic epithelium stained), as focally positive (≤25%) and as diffuse positive (>25%). A diffuse staining pattern was detected in 43.8% of CIN1 of group A, 74.2% of group B and 56.3% of group C. No p16INK4a staining was detected in 31.3% and 12.9% CIN1 lesions of groups A and B, respectively. Overall, 71.4% and 37.8% of p16INK4a-negative and diffusely positive CIN1 had regressed at follow-up, whereas 28.6% and 62.2% negative and diffusely positive CIN1 were progressed to CIN3, respectively (P<0.05). All CIN3 lesions analyzed during follow-up of group B were diffusely stained for p16INK4a. Although p16INK4a may be expressed in low-grade squamous lesions that undergo spontaneous regression, in this study, CIN1 cases with diffuse p16INK4a staining had a significantly higher tendency to progress to a high-grade lesion than p16INK4a-negative cases. p16INK4a may have the potential to support the interpretation of low-grade dysplastic lesions of the cervix uteri.
160 citations
Cited by
More filters
Book•
01 Jan 2004
3,111 citations
TL;DR: These probabilities allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection to determine the most appropriate treatment and frequency of follow-up.
2,459 citations
TL;DR: The current summary of the EAU Muscle- invasive and Metastatic Bladder Cancer Guidelines provides an up-to-date overview of the available literature and evidence dealing with diagnosis, treatment, and follow-up of patients with metastatic and muscle-invasive bladder cancer.
1,209 citations
TL;DR: It is recommended that chemotherapy be administered before radical treatment and that bladder removal be the standard of care for disease confined to the bladder for patients with muscle-invasive or metastatic BCa.
1,025 citations
TL;DR: The intensity and scope of care for NMIBC should focus on patient, disease, and treatment response characteristics, and a risk-stratified approach categorizes patients into broad groups of low-, intermediate-, and high-risk.
936 citations